Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04099277 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3435151 in Participants With Solid Tumors
A Phase 1 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT04099277: Clinical Trial Phase 1 study, sponsored by Eli Lilly and Company.
NCT04099277 is a Phase 1 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04099277, a Phase 1 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The reason for this study is to see if the study drug LY3435151 is safe in participants with advanced solid tumors.
Primary Outcome
A DLT is defined as an Adverse Event that is likely related to the study medication or combination, and fulfills any one of the following criteria, graded according to the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0: 1. Any death not clearly due to the underlying disease or extraneous causes 2. Neutropenic fever 2. Any Grade ≥3 non-hematologic toxicity 3. Grade ≥4 neutropenia or thrombocytopenia \>7 days 4. Grade ≥3 thrombocytopenia w
Interventions
- DRUG Pembrolizumab
- DRUG LY3435151
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-10-28 |
| Est. Completion | 2020-03-05 |
| Phase | Phase 1 |
Why NCT04099277 stopped before completion
NCT04099277 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04099277 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04099277 about?
NCT04099277 is a clinical study titled "A Study of LY3435151 in Participants With Solid Tumors". The reason for this study is to see if the study drug LY3435151 is safe in participants with advanced solid tumors.
What is the current status of trial NCT04099277?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2019-10-28. Estimated completion is 2020-03-05.
What interventions are being tested in trial NCT04099277?
The interventions under investigation include: Pembrolizumab (DRUG), LY3435151 (DRUG).
Who is sponsoring clinical trial NCT04099277?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04099277's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI